Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as “expects”, “will”, “anticipates”, and “estimates”; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief “snapshot” of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled “Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

Toronto, Ontario–(Newsfile Corp. – February 23, 2022) – Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K70) (“Silo Wellness” or the “Company”), a leading global psychedelics company, today announces several corporate updates.

On February 4, 2022, the Company completed its first Jamaican psilocybin retreat of 2022 entitled “Renew Your Purpose” (see press release of December 16, 2021). This five-day/four-night psilocybin-assisted retreat was centered around purpose and self-reflection with preparation focusing on themes present in author Jessica Huie’s book PURPOSE.

“I felt like a neural pathway in my brain had opened up. There was a release,” stated Whitney Leming-Salisbury, a “Renew Your Purpose” retreat participant from the United States. “The combination of yoga, ceremonies, the workshops and one on one sessions with the guides, really solidified my integration with the medicine. Before you consider any other Earth medicine, I really think psilocybin is the best first step – especially with Silo, because the approach is gradual and gentle and there is no reason to fear at all – possibly the most beautiful approach I’ve ever had to a healing therapy.”

“It is responses like Whitney’s that gives our team our own sense of purpose,” said Silo Wellness Chief Executive Officer Douglas K. Gordon. “This is why we do what we do: to safely introduce individuals to psychedelics in a legal place in the western hemisphere.”

Additional scheduled retreats can be found at www.SiloWellness.com.

Other Corporate Updates

On February 11, 2022, the Silo Wellness functional mushroom brand Marley One sponsored a live and metaverse concert “For the Love of Hip Hop” held in Savannah, Georgia. It was headlined by Outcast’s Big Boi and featured several other rap artists including Sleepy Brown, Goodie Mob, Young Dro, Lil Scrappy, Ying Yang Twins and Kurupt & Daz (see press release of February 10, 2022).

Effective February 22, 2022, the Company’s wholly-owned subsidiary and Jungle Med Inc. have mutually cancelled their letter of intent for an exclusive licensing agreement for manufacturing, marketing, and distributing the Company’s patent-pending, metered-dosing psilocybin nasal spray in Columbia and Brazil (see press release of April 15, 2021). A definitive agreement was not reached between the parties, although the company is continuing to explore potential working relationships.

For more information about Silo Wellness, please visit https://www.silowellness.com/. To buy Marley One products, please visit https://marleyone.com/.

ABOUT SILO WELLNESS

Silo Wellness is a growth-oriented holding company focused on functional mushroom and psychedelic opportunities that benefit from a unified ecosystem and exceptional leadership. Founded in 2018 and headquartered in Toronto, Silo Wellness has operations in Jamaica and Oregon. Silo Wellness is a publicly-traded company on the Canadian (CSE: SILO) and Frankfurt (FSE: CK70) exchanges and trading on the OTCQB Venture Market (OTCQB: SILFF).

Silo Wellness offers a diverse and growing portfolio of functional mushroom products, psychedelic wellness retreats in Jamaica and Oregon, cultivation of psychedelic mushrooms and truffles in Jamaica, development of a brick-and-mortar smart shop in Jamaica, and intellectual property, focused initially on the commercialization of its metered-dosing psilocybin nasal spray.

In March 2021, Silo Wellness announced a multi-year licensing agreement with the family of legendary musician Bob Marley for the exclusive worldwide rights to brand, market and sell a distinct product line of functional and psychedelic mushrooms. The Marley One line of functional mushrooms is available at www.MarleyOne.com.

For more information about Silo Wellness, please visit www.silowellness.com.

For further information, please contact:

Silo Wellness Corporate Information:
Mike Arnold, President/Director
541-900-5871
[email protected]

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION: This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates, and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to the Company’s future business plans. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, regulatory, political and social uncertainties and the potential impact of COVID-19. Such risks and uncertainties include, among others, the risk factors included in Silo Wellness’s continuous disclosure documents available on www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. Silo Wellness assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

TryptageniX, a majority-owned joint venture with CB Therapeutics, employs bioprospecting to develop new chemical entities with potential applications in mental health.

This new platform company will focus on the generation of intellectual property and further strengthen atai’s drug development pipeline of psychedelic and non-psychedelic compounds.

TryptageniX will also develop scalable and environmentally friendly biosynthetic manufacturing methods for atai’s naturally derived compounds.

NEW YORK, Dec. 09, 2021 (GLOBE NEWSWIRE) — atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the launch of TryptageniX. This new platform company will specialize in both the discovery of new chemical entities (NCEs) for the atai pipeline through bioprospecting and on biosynthesis of atai’s naturally derived development candidates. Both approaches are expected to further strengthen atai’s already robust intellectual property (IP) portfolio spanning psychedelic and non-psychedelic compounds.

Bioprospecting refers to the search for natural products from which medicines can be developed, while biosynthesis is the production of complex molecules within living organisms or cells. Both are central to TryptageniX’s approach to the development of NCEs. In addition, the development of innovative biosynthetic methods will further optimize the scalability of compound manufacturing, allowing atai to address the escalating mental health crisis in an ecologically sustainable manner.¹

“We are constantly seeking opportunities to further extend the capabilities of our platform,” said Florian Brand, Chief Executive Officer and Co-Founder of atai Life Sciences. “TryptageniX’s approach to drug discovery is highly complementary to that of EntheogeniX, our existing AI-enabled drug discovery company. The launch of TryptageniX demonstrates our ongoing commitment to harness the most promising scientific advancements of our age for the good of patients.”

“atai is delighted to be collaborating with CB Therapeutics to form TryptageniX,” said Srinivas Rao, Chief Scientific Officer and Co-Founder of atai Life Sciences. “We both share a strong commitment to driving novel approaches in the treatment of mental health disorders. This is yet another important step forward for atai in developing innovative and scalable solutions to serve the ever-growing needs of patients and support our dynamic clinical development strategy.”

“CB Therapeutics is very excited to be joining forces with atai Life Sciences with the launch of TryptageniX,” said Dr. Jacob Vogan, Chief Scientific Officer of CB Therapeutics. “It is our shared ambition that this platform will lead the way in exploring psychedelic-centric biosynthesis solutions and enable the discovery of important new chemical entities. Sensitivity to sustainability and the wider ecosystem is paramount, which we believe can be accomplished through innovative biosynthetic manufacturing methods for naturally derived compounds.”

“Our expertise in synthetic biology, precision fermentation, and downstream processing, along with the opening of our new world-class pilot facility will enable rapid development and deployment of much needed, cutting-edge solutions for mental health and wellness, and we are very excited to be at the forefront of this revolution,” said Sher Ali Butt, Chief Executive Officer of CB Therapeutics.

Naturally derived compounds play an important role across drug development for the central nervous system (CNS). TryptageniX will be a strong complement to atai’s existing drug discovery and development expertise, while also allowing atai to minimize its ecological footprint and ensure a sustainable supply chain for the future.

References:

1. Rehm J, Shield KD. Global Burden of Disease and the Impact of Mental and Addictive Disorders. Curr Psychiatry Rep. 2019;21(2):10.

About atai Life Sciences
atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to acquiring, incubating and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders.

atai’s business model combines funding, technology, scientific and regulatory expertise with a focus on psychedelic therapy and other drugs with differentiated safety profiles and therapeutic potential. By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies, seeking to effectively treat and ultimately heal mental health disorders.

atai’s vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. atai has offices in New York, London, and Berlin. For more information, please visit www.atai.life.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “initiate,” “could,” “would,” “project,” “plan,” “potentially,” “preliminary,” “likely,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements relating to, among other things: statements regarding TryptageniX and biosynthetic NCE development, the success, cost and timing of development of our product candidates, including the progress of preclinical and clinical trials and related milestones; our business strategy and plans; potential acquisitions; and the plans and objectives of management for future operations and capital expenditures. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond our control and which could cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these forward-looking statements.

We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including without limitation: we are a clinical-stage biopharmaceutical company and have incurred significant losses since our inception, and we anticipate that we will continue to incur significant losses for the foreseeable future; we will require substantial additional funding to achieve our business goals, and if we are unable to obtain this funding when needed and on acceptable terms, we could be forced to delay, limit or terminate our product development efforts; our limited operating history may make it difficult to evaluate the success of our business and to assess our future viability; we have never generated revenue and may never be profitable; our product candidates contain controlled substances, the use of which may generate public controversy; clinical and preclinical development is uncertain, and our preclinical programs may experience delays or may never advance to clinical trials; we rely on third parties to assist in conducting our clinical trials and some aspects of our research and preclinical testing, and those clinical trials, including progress and related milestones, may be impacted by several factors including the failure by such third parties to meet deadlines for the completion of such trials, research, or testing, changes to trial sites and other circumstances; we currently rely on qualified therapists working at third-party clinical trial sites to administer certain of our product candidates in our clinical trials and we expect this to continue upon approval, if any, of our current or future product candidates; if third-party sites fail to recruit and retain a sufficient number of therapists or effectively manage their therapists, our business, financial condition and results of operations would be materially harmed; we cannot give any assurance that any of our product candidates will receive regulatory approval, which is necessary before they can be commercialized; research and development of drugs targeting the central nervous system, or CNS, is particularly difficult, and it can be difficult to predict and understand why a drug has a positive effect on some patients but not others; we face significant competition in an environment of rapid technological and scientific change; third parties may claim that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and may prevent or delay our development and commercialization efforts; a change in our effective place of management may increase our aggregate tax burden; we identified material weaknesses in connection with our internal control over financial reporting; and a pandemic, epidemic, or outbreak of an infectious disease, such as the COVID-19 pandemic, may materially and adversely affect our business, including our preclinical studies, clinical trials, third parties on whom we rely, our supply chain, our ability to raise capital, our ability to conduct regular business and our financial results. Other risk factors include the important factors described in the section titled “Risk Factors” in our final prospectus, dated June 17, 2021, filed with the Securities and Exchange Commission (“SEC”) pursuant to Rule 424(b) under the Securities Act, and in our other filings with the SEC, that may cause our actual results, performance or achievements to differ materially and adversely from those expressed or implied by the forward-looking statements.

Any forward-looking statements made herein speak only as of the date of this press release, and you should not rely on forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, performance, or achievements reflected in the forward-looking statements will be achieved or will occur. Except as required by applicable law, we undertake no obligation to update any of these forward-looking statements for any reason after the date of this press release or to conform these statements to actual results or revised expectations.

Contact Information

Media Contact:
Camilla Dormer
VP, Communications
Email: [email protected]

Investor Contact:
Chad Messer
VP, Investor Relations
Email: [email protected]

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Research study follows deployment of Cognetivity’s ICA in Ketamine One’s North American clinics and will open up novel, tailored use cases in burgeoning mental health market

VANCOUVER, BC, Dec. 2, 2021 /CNW/ – Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity“) (CSE: CGN) (OTCQB: CGNSF) (FWB: 1UB) today announced that it is entering into a collaborative partnership with KetamineOne Capital Ltd (“Ketamine One“) to study and develop assessments for depression and post-traumatic stress disorder (“PTSD“).

In the initial stage of the partnership, Cogentivity and Ketamine One will partner on two separate clinical studies, one for depression and the second for PTSD. Protocols for both studies have received Institutional Review Board (“IRB“) approval and patient recruitment is expected to occur in early 2022. Ketamine One’s wholly owned subsidiary, KGK Science Inc., will lead the study, while Cognetivity will lead the analysis.

Ketamine One is a next-generation health and wellness company focused on transforming the treatment of mental health through the provision of ketamine-assisted therapy and psychedelic medicines. Based in Canada and operating clinics throughout North America, the firm is dedicated to building the critical infrastructure needed to provide breakthrough and life-changing treatments for conditions such as anxiety, depression, PTSD, chronic pain and addiction.

Cognetivity’s Integrated Cognitive Assessment (“ICA“) technology has already been deployed throughout Ketamine One’s network of clinics in North America after the two companies entered into a commercial agreement earlier this year. In the latest phase of their collaboration, the ICA will be used to monitor changes in patients’ cognitive ability as they undergo ketamine-assisted treatment for depression and PTSD.

The clinical studies will add to the extensive body of data validating the ICA’s use as a cognitive testing tool. It has already been widely deployed in clinical care, from North America and the Middle East to clinics in the UK’s National Health Service. The project will also generate novel intellectual property regarding the ICA’s predictive and long-term monitoring capabilities – not only on a stand-alone basis, but in combination with additional variables, including data from wearable devices, to support the creation of dedicated new products for specialist care in the areas of depression and PTSD.

It is well known that there is vast potential for improvement in the treatment of such conditions. According to the WHO, mental health disorders account for 28% of the global burden of disability-adjusted life years among non-communicable diseases – more than cardiovascular disease or cancer. Every year, more than 12 billion working days are lost due to mental health conditions, costing the global economy USD 16 trillion in economic output between 2011 and 2030. The global market for PTSD therapeutics is expected to reach USD 3.1 billion by 2027, with the global market for the treatment of anxiety disorders and depression predicted to exceed 13 billion by the same year.

“We’re delighted to be extending our relationship with Cognetivity through this exciting new research project,” said Adam Deffett, Interim CEO of Ketamine One. “Depression and PTSD are sadly very common conditions and existing approaches to treating them leave a lot to be desired. With the crucial involvement of the ICA, this study will further demonstrate the power of our therapies as we pursue our goal of changing how mental health is treated across North America.”

Also commenting on the announcement, Dr Sina Habibi, CEO of Cognetivity, said, “It’s great to be working with Ketamine One on these clinical studies. We are very excited about obtaining high-quality clinical validation data on the use of the ICA to assess and monitor patients with depression and PTSD, and developing exciting new technology to better serve this important market. These disease areas represent important use cases for the ICA beyond its core application as a clinical tool for early detection of cognitive impairment. Expanding into applications such as this demonstrates the strength of the technology’s fundamental capabilities and the ongoing global need for much-improved cognitive testing across a huge number of areas.”

About Cognetivity Neurosciences Ltd.

Cognetivity is a technology company that has created a cognitive testing platform for use in medical, commercial and consumer environments. Cognetivity’s ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of cognitive impairment by testing the performance of large areas of the brain. The ICA is currently available for clinical use in the USA, UK and Europe, with regulatory approval for other regions planned for 2022.

About Ketamine One

KetamineOne Capital Limited (formerly Myconic Capital Corp.) is a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments. It is working to provide the critical infrastructure needed to develop and deliver breakthrough mental health treatments. Currently, Ketamine One has a network of clinics across North America, with plans to further consolidate the highly fragmented industry. KGK Science Inc. is the Company’s wholly owned contract research division, which places it at the forefront of premium clinical research based on the subsidiary’s history and extensive experience in pharmaceuticals, cannabis, and the emerging psychedelic medicine industries. As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.

For more information, please visit: www.ketamine.one.

ON BEHALF OF THE BOARD
“Sina Habibi”
Sina Habibi
Chief Executive Officer and Director

FORWARD-LOOKING STATEMENTS:

Certain statements included in this news release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “assume” “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This news release contains forward looking statements. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Such statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Readers should not place undue reliance on the Company’s forward-looking statements.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Cognetivity Neurosciences Ltd

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Vancouver, British Columbia – TheNewswire – October 7, 2021 – Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to announce that MindBio Therapeutics is developing a mental health technology platform to integrate with psychedelic treatments in clinical trials in patients suffering pain who are susceptible to depression, existential distress and anxiety.

MindBio, a 100% owned subsidiary of Blackhawk, through its recent collaboration agreement with Digital Mind Technology, has begun to develop solutions to prevent deteriorating mental health. Cancer patients suffering pain will be able to access these solutions through their mobile devices, desktops and wearables.

Pain, endured unsustainably can lead to depression and anxiety. The foundational research and product development being progressed by MindBio, in its collaboration with Digital Mind Technology, is about creating new digital models to intervene in pain management experienced in cancer patients. The aim is to create interventions using technology to prevent negative mental health outcomes and apply these learnings to diverse patient cohorts.

MindBio Therapeutics aims to commercialize the intellectual property globally. As recently seen in Europe, some of these digital and web applications have the potential to reach reimbursement status, where therapeutic bodies and governments provide funding for the use of these digital therapeutics by doctor’s prescription. The first prescription digital health applications were approved for reimbursement in Germany in September 2020 by the Federal Institute for Drugs and Medical Devices. Since then, many web applications have been reimbursed for use in a wide range of conditions including tinnitus, insomnia, anxiety, pain, obesity, migraine, and multiple sclerosis1.

Concurrently, MindBio Therapeutics through its psychedelics microdosing program at the University of Auckland in New Zealand, has had Phase 2 clinical trials microdosing LSD in late-stage cancer patients approved by the New Zealand government who have committed NZ$250,000 in funding to support this important efficacy work. In these trials, a small group of late-stage cancer patients will be trialled on a drug only vs a drug and mindfulness therapy and if successful will lead to a much larger phase 2 clinical trial.

MindBio is actively partnering and looking for acquisitions in technology solutions, clinics and treatments that fit strategically alongside its clinical trial drug development research activities.

“We are very pleased to be pioneering this collaboration and leading a multi-disciplinary framework in the psychedelics and mental health treatments ecosystem” says Frederick Pels, CEO of Blackhawk Growth Corp. “This important work in mental wellness technology, digital therapies and psychedelics clinical research in oncology is paving the way for novel and emerging treatments to change the way mental health treatments are provided around the world.”

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, and MindBio Therapeutics. Blackhawk continues to bring its investments to cash flow and is growing at an exceeding pace.

The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

1. 1.https://www.pharmaceutical-technology.com/comment/digital-therapeutics-germany

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

[email protected]

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to transaction and future operations of MindBio Therapeutics Pty Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

By Rebecca Victoria Olmos

In April, co-chairs of the Congressional Cannabis Caucus, Representatives Barbara Lee (D-CA) and Dave Joyce (R-OH), joined Senator Brian Schatz (D-HI) to introduce the Veterans Medical Marijuana Safe Harbor Act of 2021. This bill would allow Veterans Affairs (VA) doctors to discuss and recommend cannabis as treatment in states where weed is legal and research its effects.

Because of weed’s federally illegal status, the VA cannot recommend it as a possible treatment option. There are also limitations on the ability to conduct medical research on cannabis and its effects on different mental health conditions, physical ailments, and how it interacts with other medications. These are crucial factors to consider when treating a human with layers of medical conditions and trauma.

“It has been scientifically proven that medical marijuana has a considerable impact in treating conditions common with veterans when they return from service, like chronic pain and PTSD,” Lee said in a press release.

Veterans who return safely home often deal with more than one health issue due to their service. According to the National Academy of Sciences, these include anxiety, depression, post-traumatic stress disorder, chronic pain, and an array of others.

Doctors with the VA currently treat these ailments with prescription drugs. While these drugs can be helpful, they also can have adverse side effects like headaches, gastrointestinal conditions, and seizures.

Veterans often self-prescribe cannabis as an alternative medicine because it has less drastic side effects. A 2019 nationwide study done by the Iraq and Afghanistan Veterans of America found that 75% of veterans would consider using cannabis as treatment if it was made available to them.

The Veterans Medical Marijuana Safe Harbor Act of 2021 would provide five-year safe harbor protection for veterans and their doctors. This legislation is one of a few bills introduced this year to lift federal restrictions on cannabis research and recommendations for veterans.

The psychedelics industry is poised to become a nearly $7 billion market by 2027, according to Data Bridge Market Research, driven by the potential to revolutionize the treatment of mental health disorders. While investors have many options in the space, the best positioned companies are combining delivery mechanisms with novel compounds to create IP strategies.

Let’s take a look at why delivery mechanisms matter and how Cybin Corp. is leveraging sublingual delivery to revolutionize psychedelic therapies.

What Are Delivery Mechanisms?

Most pharmaceuticals come from natural sources—and the same is true for both cannabis and psychedelics. Of course, the final product that people pick up from the pharmacy is typically pill, capsule, spray, suppository or other delivery mechanism.

Delivery mechanisms play an important role in ensuring the bioavailability and optimal delivery of pharmaceutical compounds. For instance, extended release tablets slowly release an active pharmaceutical ingredient, or API, over time rather than all at once. These capabilities can be transformative for chronic pain relief therapies by making a once-a-day option.

Aside from convenience and performance, delivery mechanisms may be required for any efficacy. The most common problem experienced by some pharmaceuticals is first-pass metabolism in the liver. While it’s possible to simply increase the dosage, there are many instances where high doses become toxic, making a delivery mechanism essential.

Benefits of Delivery Mechanisms

The most obvious benefit of a delivery mechanism is that it improves the performance of a pharmaceutical compound or makes it safe to use. But aside from these benefits, there are several other reasons to develop innovative delivery mechanisms.

Delivery mechanisms are a common way to patent natural compounds or extend expiring patents. While patients and consumers can still access cheap natural compounds or legacy products, these delivery mechanisms typically improve the efficacy of the compound or offer other benefits that may encourage commercial adoption.

The development of delivery mechanisms themselves also represents unique intellectual property. Investors in these companies benefit from both a potentially efficacious and unique delivery, as well as the ability to leverage the same delivery technology across a wide range of different compounds—or even the ability to license it to others.

Cybin’s Psychedelic Approach

Cybin Corp. is focused on psychedelic drug development, unique delivery mechanisms, improved novel compounds and protocols that target psychiatric and neurological conditions.

Watch Cybin CEO Doug Drysdale discuss the innovative delivery mechanism:

Click here to learn more about investing in Cybin and receive corporate updates

The company’s wholly owned subsidiary, Serenity Life Sciences, has developed a fast-acting sublingual delivery strip technology that provides both improved bioavailability and greater convenience for patients. In particular, sublingual delivery offers fast access to the bloodstream and bypasses second-pass metabolism in the liver.

The unique delivery mechanism is being used in a Phase II randomized, parallel group, bioequivalence study of psilocybin for the treatment of Major Depressive Disorder. If successful, the company could become one of the first life science companies to launch a fully approved psilocybin product targeting depression.

Watch CEO Doug Drysdale outline the company’s clinical trial strategy:

Click here to learn more about investing in Cybin and receive corporate updates

Looking Ahead

Cybin Corp. could become one of the first life sciences companies to commercialize psilocybin for the treatment of depression. With an innovative delivery mechanism, the company developed a patentable product with potentially significant advantages over other forms of psilocybin, creating an attractive commercial opportunity.

The company plans to go public through a reverse-takeover of Clarmin Explorations on the TSX Venture exchange. In connection with the going public transaction, the company plans to raise a minimum of $14 million and a maximum of $21 million to fund its ongoing research and development activities.

For more information, visit the company’s website or download the investor presentation.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

The COVID-19 pandemic has led to dramatic changes in healthcare. In addition to mobilizing a vaccine in record time, the pandemic could permanently alter the way that many people seek medical care, shifting from in-person to telehealth. These changes have created an enormous opportunity for companies to innovate in the remote delivery of health services.

Let’s take a look at the growth in telehealth and how Mydecine Innovation Group’s (CSE: MYCO) (OTC: MYCOF) (FFT: 0NF) subsidiary, MindLeap, aims to play a leading role.

Telehealth Poised for Growth

The telehealth market is projected to become a nearly $560 billion market by 2027, according to Fortune Business Insights, which represents a blistering 25.2% compound annual growth rate. While the COVID-19 pandemic has accelerated demand for e-visits, telehealth also offers easier access to required doctors, lower patient waiting times and greater cost efficiency.

Growth in the Global Telehealth Market – Source: Grand View Research

These growth rates have led to strong growth among the handful of public companies focused on telehealth. There has also been growing M&A interest in the space following Teladoc Health’s move to acquire InTouch Health and Zava’s $32 million Series A that was funded by HPE Growth, representing a significant investment in the space.

Performance of Telehealth Public Companies – Source: Yahoo! Finance

MindLeap Launches Platform

MindLeap Health  recently launched a telehealth platform that will be officially available on Apple iOS and Google Android stores on September 30, 2020. The platform enables users to browse vetted and experienced specialists, easily schedule appointments and purchase mental health services through an intuitive and easy to use application.

Mental health specialists using the MindLeap platform can easily manage their virtual practice on their own terms by setting their own prices and choosing the hours that they work each week. MindLeap takes a 9% cut of each session’s fee in exchange for providing access to its built-in user base and technology. 

[embedded content]

Click the image to see an introduction to the MindLeap app and gain early access

Unlike other mental health platforms, MindLeap is uniquely designed to offer psychedelic integration services with over 30 professionals able to offer mental health support. These specialists can help clients through a systematic process that turns psychedelic experiences into something practical—although they don’t remotely guide the actual experiences.

Click here to learn more about investing in the MindLeap mental health platform

Looking Ahead

Mydecine Innovation Group (CSE: MYCO) (OTC: MYCOF) (FFT: 0NF) is uniquely positioned to benefit from the growth in the telehealth market, and in particular, growing demand for mental health services. As the psychedelic market matures, the company’s platform has an opportunity to experience significant growth as other telemedicine companies in this enormous and fast growing market. 

In addition to MindLeap, Mydecine Innovation Group is conducting the world’s first clinical trial of psilocybin for the treatment of post-traumatic stress disorder, or PTSD, a market worth $7.8 billion. The company is entering into Phase I clinical trials this month and has various other psychedelic drug candidates in development at their laboratories in Denver and Alberta. 

Investors may want to take a closer look at the stock given its unique exposure to two rapidly growing markets—telehealth and psychedelics.

For more information, visit the company’s website or download their investor presentation.

Sign up here to get access to the Mindleap app.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

DENVER, Sept. 24, 2020 (GLOBE NEWSWIRE) —  Mydecine Innovations Group Inc. (MYCO.CN) (MYCOF) (0NF.F) (“Mydecine” or the “Company”), is pleased to announce that its subsidiary Mindleap Health’s (“Mindleap” ) telehealth platform will be officially available for download from the iOS and Android stores on September 30, 2020.

Mindleap was founded with the goal of enhancing the wellbeing of millions of people that struggle with mental health problems. By combining traditional telemedicine with mood and behavior analytics, the Mindleap platform offers a powerful set of tools for managing mental healthcare.

Joshua Bartch, Mydecine Director and CEO commented: “Our team is thoroughly impressed by the user experience and capabilities of Mindleap and we are excited to be able to support such an innovative and mission-driven company. The adoption of telemedicine has significantly increased in 2020 and virtual health-care interactions are on pace to top 1 billion, providing a big opportunity that I’m confident Mindleap can capitalize on.”

Platform Overview
Through Mindleap, users can browse vetted and experienced specialists and easily schedule appointments and purchase mental health services. Specialists on Mindleap benefit from the platform’s full freedom to manage their virtual practice on their terms; setting their own prices and choosing the hours they work each week (with no minimums or maximums).

Mindleap has established a model that creates value by facilitating exchanges between mental health specialists and people needing mental health services. The company is focused on creating a community with network effects that allows users to interact and transact with specialists in order to improve their mental health. Mindleap is free to use for end users and for specialists who want to build a profile. It is only when an end user purchases services on the platform that Mindleap charges a 9% fee as a percentage of each session.

Mindleap Founder and CEO, Nikolai Vassev commented: “The world is seeing a crisis that is having unprecedented effects on the wellbeing of millions of people. Mental health is hands down one of today’s most important problems and our team is thrilled to officially announce the launch of our platform.”

Effective Solutions for Psychedelic Integration

Mindleap is the world’s first telemedicine platform uniquely designed to offer psychedelic integration services and currently has over 30 professionals available to offer mental health support to clients. Psychedelics offer a window into the mind, and integration specialists help clients through a systematic process that can turn their psychedelic experience into something practical. This can include helping make sense of unique images or ideas that came to mind during a psychedelic experience, as well as setting new goals, habits and behaviours that can help to improve a person’s life.

Over the past decade, a growing body of research published by leading academic institutions such as Imperial College of London, Yale University, and Johns Hopkins University has demonstrated that psychedelic medicines like psilocybin (the active compound found in magic mushrooms), MDMA, and ketamine can be used as effective and safe treatments for a variety of mental health conditions, which often significantly outperform today’s standard pharmacological treatments and therapies.

While Mindleap does not encourage people to spend time on their phones while taking psychedelic substances, and does not facilitate psychedelic use via the platform, the company recognizes a deep need for people to connect with trained professionals who can help them discuss and understand their individual psychedelic experiences.

Dr. Danielle Wise, Director of Product Development commented: “When designing Mindleap, we focused on combining the real need for integration after a psychedelic experience with modern and innovative technologies that can help improve the overall therapeutic experience along with outcomes. As the decriminalization and legalization movement progresses we aim to be at the forefront in supporting the psychedelic community and people that are searching for real solutions that are effective but also safe and properly informed.”

Later this year, Mindleap will be expanding by adding mental health specialists with different aptitudes as well as a digital therapeutics marketplace that will allow users to access comprehensive mental health programs. These additional offerings will focus on various topics such as meditation, addiction, psychedelic integration, drug harm reduction and holistic wellness.

Mindleap Puts User Privacy and Security First

Mindleap recognizes the immense responsibility in handling people’s mental health data, and is setting a new standard for both user privacy and data integrity. Foremost, Mindleap will never sell or license user data, including electronic Personal Health Information (ePHI) to anyone. Mindleap also has strict policies around how data is handled and stored; all data is encrypted in-transit and at-rest, and specialists are not permitted to save their clients’ data – they can only view it temporarily while the user chooses to share it during a video call.

Mindleap’s software development team has built the platform to meet all HIPAA guidelines by implementing secure electronic access to health data and remains in compliance with privacy regulations and best practices.

Mindleap’s Chief Technology Officer Simon Abou-Antoun commented: “Mindleap was designed to improve upon existing software solutions our development team is already working on enhancing our capabilities so Mindleap can capture market share in the fast growing digital health market that is estimated to reach USD 510.4 billion by 2025.”

Official Launch Date
Mindleap will be available for iOS and Android on Wednesday, September 30th, 2020. Register to be the first to download and get $25 of free credits on Mindleap.

About Mindleap Health
Mindleap is a telehealth solution that helps people connect with mental health specialists that can empower them to thrive and develop habits for a healthy mind. The Mindleap platform brings convenience, improves access to treatments and can lead to more personal breakthroughs. Mindleap’s proprietary platform is designed by clinical psychologists and neuroscientists to provide professional support and personalized treatment for every user. Our vision is for a world where people can make lasting life changes by having advanced tools and access to expert mental health professionals right from the palm of their hand.

Learn about Mindleap Health

Learn about The Past and Future of Psychedelics as a Medicine

Apply to become a Specialist on Mindleap

Watch the Mindleap Platform Overview Video

About Mydecine Innovations Group

Mydecine Innovations Group is a publicly traded life sciences parent company dedicated to the development and production of adaptive pathway medicine, natural health products and digital health solutions stemming from fungi. Mydecine’s experienced cross functional teams have the dynamic capabilities to oversee all areas of medicine development including synthesis, genetic research, import/export, delivery system development, clinical trial execution, through to product commercialization and distribution. By leveraging strategic partnerships with scientific, medical, military, and clinical organizations, Mydecine is positioned at the forefront of psychedelic medicine naturally derived from fungi, therapeutic solutions, and fungtional mushroom vitality products. Our portfolio of unified companies, including Mydecine Health Sciences, Mindleap Health, and NeuroPharm focus on providing innovative and effective options that can provide millions of people with a healthier quality of life.

For further information about Mydecine Innovations Group Inc., please visit the Company’s profile on SEDAR at www.sedar.com or visit the Company’s website at www.mydecine.com.

On behalf of the Board of Directors:
Joshua Bartch, Chief Executive Officer
[email protected]

Corp Communication:
Charles Lee, Investor Relations
[email protected]

Public Relations:
Cynthia Salarizadeh, Public Relations
[email protected]

*Mindleap Health Platform Services Disclaimer: Mindleap Services are designed to connect users of our Services with mental health specialists so as to receive assistance and guidance with integrating their prior psychedelic or consciousness-expanding experiences and translating them into positive changes. Our Services are not designed or intended for the integration or translation of a presently occurring psychedelic experience and must not be used for that purpose. Psychedelic substances are legally controlled or prohibited in many jurisdictions, but there are legal means to have a psychedelic or conscious-expanding experience in certain circumstances. You are solely responsible and liable for adequately informing yourself of the Laws of your jurisdiction before using our Services and determining if use of our Services and the receipt of Specialist Services (defined below) is lawful in your jurisdiction. Our Services are meant to be used exclusively in connection with lawful activities and must not be used in connection with illegal substances or illegal activities. Without limiting the previous sentence, you are not permitted to promote, procure, consume, or sell illegal substances through the Services. Do not use psychedelic substances if doing so is unlawful in your jurisdiction. Possession of psychedelic substances in violation of applicable laws can carry significant penalties, including years of incarceration.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof. This news release contains forward-looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, without limitation, the availability and continuity of financing, the ability of the Company to adequately protect and enforce its intellectual property, the Company’s ability to bring its products to commercial production, continued growth of the global adaptive pathway medicine, natural health products and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale and use of the Company’s products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation. This news release does not constitute an offer to sell securities and the Company is not soliciting an offer to buy securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. This news release does not constitute an offer of securities for sale in the United States. These securities have not and will not be registered under United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States or to a U.S. Person unless so registered, or an exemption from registration is relied upon.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.